Harry J Long
Affiliation: Mayo Clinic
- Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometriumHarry J Long
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Gynecol Oncol 100:501-5. 2006..The North Central Cancer Treatment Group Phase III trial compared efficacy of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with doxorubicin plus cisplatin (AC) for patients with advanced endometrial cancer...
- Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group studyHarry J Long
Department of Medical Oncology, Mayo Clinic College of Medicine, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
Gynecol Oncol 99:339-42. 2005....
- Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group studyHarry J Long
Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
Gynecol Oncol 100:537-43. 2006..The primary endpoint was overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL) as secondary objectives...
- Management of metastatic cervical cancer: review of the literatureHarry J Long
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
J Clin Oncol 25:2966-74. 2007..This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer...
- Current research directions for locally advanced cervix cancerHarry J Long
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Oncol Rep 5:468-72. 2003..Well-designed, randomized, prospective clinical trials are needed for a more thorough evaluation of these preliminary findings and to set research directions for the next several years...
- Prevention, diagnosis, and treatment of cervical cancerHarry J Long
Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:1566-74. 2007..Current recommendations for surgical treatment, concurrent chemotherapy, and radiation therapy and recent advances in systemic therapy for advanced or metastatic cervical cancer are reviewed...
- Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group StudyHarry J Long
Mayo Clinic College of Medicine, Rochester, MN, USA
J Clin Oncol 23:4626-33. 2005..014), and response rates of 27% and 13%, respectively. CONCLUSION: This is the first randomized phase III trial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advanced cervix cancer...
- Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literatureHarry J Long
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Am J Clin Oncol 25:547-51. 2002..Its progression-free survival and overall survival rates appear promising. These results need to be confirmed within a large randomized phase III clinical trial...
- High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapyAndrea Mariani
Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Gynecol Oncol 95:120-6. 2004..New target-based algorithms for the 35% of endometrial cancer patients deemed at risk should be incorporated in the development of future prospective multimodality clinical trials predicated on site(s) of recurrence...
- Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancerSean C Dowdy
Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Am J Obstet Gynecol 186:1167-73. 2002..Compared with historic control subjects, multimodal treatment may be associated with improved rates of pelvic control...
- Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?Giovanni D Aletti
Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Gynecol Oncol 104:212-6. 2007..Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the "time to chemotherapy" (TTC) interval on survival...
- Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis
Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Res 70:875-82. 2010..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients...
- Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literatureMariam M Alhilli
Department of Obstetrics and Gynecology Medical Oncology Obstetrics and Gynecology, Division of Gyencologic Oncology, Mayo Clinic, Rochester, Minnesota, USA
J Obstet Gynaecol Res 38:340-4. 2012..We present a heavily pre-treated, multi-operated patient who experienced significant tumor shrinkage following treatment with an aromatase inhibitor for her recurrent granulosa cell tumor...
- Second-line and subsequent therapy for ovarian carcinomaPrema P Peethambaram
Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
Curr Oncol Rep 4:159-64. 2002..Whole abdominal radiotherapy for relapsed microscopic disease should be studied in prospective randomized trials. Women with advanced ovarian carcinoma should continue to be encouraged to participate in well-designed clinical trials...
- Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young
Gynecologic Oncology Group, Administrative Office, Four Penn Center, 1600 John F Kennedy Blvd, Suite 1020, Philadelphia, PA 19103, USA
J Clin Oncol 21:4350-5. 2003..Materials and..
- Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology GroupMahesh A Varia
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
J Clin Oncol 21:2849-55. 2003....
- Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup studyGeorge A Omura
University of Alabama at Birmingham, Birmingham, AL, USA
J Clin Oncol 21:2843-8. 2003..Doubling the filgrastim dose from 5 to 10 microg/kg did not reduce the probability of neutropenic fever after high-dose paclitaxel...
- Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group StudyBradley J Monk
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
J Clin Oncol 23:4617-25. 2005..CONCLUSION: Despite increased toxicity, CT did not significantly reduce patient QOL when compared with cisplatin alone. Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer...
- A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinomaRanjana Advani
Oncology Division, Stanford University Medical Center, 269 Campus Drive, Stanford, CA 94305-5151, USA
Cancer 100:321-6. 2004..CONCLUSIONS: When it was administered as a single agent, aprinocarsen did not have significant clinical activity in patients with advanced ovarian carcinoma. Further study may be warranted in combination with platinum-based regimens...